<DOC>
	<DOCNO>NCT00445796</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority , term clinical parasitological efficacy Day 14 , administration Arsucam® single daily intake versus two daily intake . Secondary Objective : To compare clinical safety two treatment regimen .</brief_summary>
	<brief_title>Arsucam® ( Artesunate + Amiodaquine ) Efficacy TOLerance</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>weigh ≥ 10 kg reside area cover investigate centre throughout entire followup period axillary temperature ≥ 37.5 degree Celsius history fever within previous 24 hour Plasmodium falciparum density blood range 1000 100,000 asexual form per cubic millimetre presence least one sign severe malaria clinical danger sign : prostration , consciousness disorder , recent repeat convulsion , respiratory distress , inability drink , uncontrollable vomiting , macroscopic haemoglobinuria , jaundice , haemorrhagic shock , systolic Blood Pressure &lt; 70 mmHg adult &lt; 50 child , spontaneous bleeding , inability sit stand serious concomitant disease allergy one investigational medicinal product pregnant woman breastfeed woman . documented intake antimalarial suitable dosage within seven day prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>